|
|
Bristol-Myers Squibb Co.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
BMS returns $475M IL-12 oncology asset to Dragonfly’s pond...................." Fierce Biotech has contacted BMS to find out why they are handing back the asset, but the company did not respond as of publication. The announcement about DF6002 comes just days after BMS announced the planned departure in the summer of BMS R&D head Rupert Vessey. Since 2017, BMS and Dragonfly have inked several deals for oncology and neuroinflammation targets. BMS is still running phase 1 trials for two of Dragonfly’s drug candidates, both of which are based around the biotech’s multi-specific Natural Killer (NK) cell engaging therapies platform, dubbed TriNKET. Just last month, the Big Pharma paid $25 million upfront to license a neuroinflammation TriNKET candidate from Dragonfly.".............. |
|
|
return to message board, top of board |
| Msg # | Subject | Author | Recs | Date Posted |
| 10798 | Re: BMS returns $475M IL-12 oncology asset to Dragonfly’s pond | grafzeppelin | 2 | 2/6/2023 2:55:13 PM |
| 10799 | Re: BMS returns $475M IL-12 oncology asset to Dragonfly’s pond | JBWIN | 4 | 2/6/2023 3:51:30 PM |
